Ipsen agreed to acquire Clementia for up to $1.31B, comprising $1.04B upfront ($25/share) plus a CVR of $6/share (~$263M) tied to acceptance of palovarotene NDA filing. Adds rare bone disease assets including palovarotene for fibrodysplasia ossificans progressiva and multiple osteochondromas.